SEngine Precision Medicine, an AI-powered precision oncology platform, has raised USD 10 million in a Series A2 round led by Washington Research Foundation with participation from other existing investors. The latest funding brings the total funds raised to USD 19 million. 

The funds will be used to expand its human resource and lab space to support drug discovery, strategic partnerships, and clinical trials of the PARIS Test platform. The platform predicts drug responses for patients with solid tumors.